BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Verastem\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Verastem\, Inc.'s drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07554859-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:GFH375: Phase 2 readout est. (NCT07554859)
DESCRIPTION:GFH375\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: GFH375 M
 onotherapy and Combination Therapy as First-Line Treatment for Advanced KR
 AS G12D-Mutant Non-Small Cell Lung Cancer\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0755
 4859
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644559-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07644559)
DESCRIPTION:GFH375\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStudy: A 
 Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Can
 cer\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07644559
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659782-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07659782)
DESCRIPTION:GFH375\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung 
 Cancer\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07659782
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659795-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07659795)
DESCRIPTION:GFH375\, phase 2.\nStudy: A Phase 2 Study of VS-7375 in Patient
 s With KRAS G12D-Mutated Colorectal Cancer\nEstimated primary completion: 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0765979
 5
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262567-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 3 readout est. (NCT07262567)
DESCRIPTION:GFH375\, phase 3.\nStudy: Phase III Study to Compare GFH375 and
  Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Canc
 er\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07262567
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259590-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:GFH375: Phase 1/2 readout est. (NCT07259590)
DESCRIPTION:GFH375\, phase 1/2.\nStudy: A Study of GFH375 Combined With Cet
 uximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G1
 2D Mutation\nEstimated primary completion: July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07259590
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747506-11026@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT07747506)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: Continued Access to Avutometinib in Combination Wi
 th Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (
 LGSOC)\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-c
 o-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07747506
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500676-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:GFH375: Phase 1/2 readout est. (NCT06500676)
DESCRIPTION:GFH375\, phase 1/2.\nStudy: A Study of GFH375 in Patients With 
 Advanced Solid Tumors With KRAS G12D Mutations\nEstimated primary completi
 on: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh
 375#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06500676
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784374-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:GFH375: Phase 2 readout est. (NCT07784374)
DESCRIPTION:GFH375\, phase 2.\nStudy: A Phase II Study of GFH375 Combined W
 ith GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Lo
 cally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS
  G12D Mutation\nEstimated primary completion: 31 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07784374
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072781-11026@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 3 readout
  est. (NCT06072781)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 3\, 
 Ovarian Cancer.\nStudy: A Study of Avutometinib (VS-6766) + Defactinib (VS
 -6063) in Recurrent Low-Grade Serous Ovarian Cancer\nEstimated primary com
 pletion: 15 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06072781
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913360-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:GFH375: Phase 3 readout est. (NCT07913360)
DESCRIPTION:GFH375\, phase 3.\nStudy: GFH375 Plus Cetuximab vs Investigator
 's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorecta
 l Cancer\nEstimated primary completion: November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07913360
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GFH375: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:GFH375\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Phas
 e 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668752-2279@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:GFH375: Phase 3 readout est. (NCT07668752)
DESCRIPTION:GFH375\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lu
 ng Cancer With KRAS G12D Mutation\nEstimated primary completion: 30 June 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07668752
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
